Abstract
There is a rapid expansion in the number of new anti-cancer drugs with remarkably different mechanisms of action that can augment traditional chemotherapy. As these agents are often used in combination with traditional chemotherapy testing the effects of these novel agents has proven difficult requiring large sample sizes to detect relatively small differences in patient survival. Despite the wide variety of mechanisms, most new drugs are thought to ultimately induce apoptosis of tumor cells or their supportive vasculature. Imaging agents that can non-invasively monitor apoptosis in response to these new drugs could therefore help streamline the drug development process. They may also help guide oncologists to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug. In this article we will outline the existing imaging agents and modalities that are currently undergoing clinical testing and those that could be rapidly translated into humans.
Anti-Cancer Agents in Medicinal Chemistry
Title: Apoptosis Imaging: Anti-Cancer Agents in Medicinal Chemistry
Volume: 9 Issue: 9
Author(s): Francis G. Blankenberg
Affiliation:
Keywords: Apoptosis, SPECT, PET, MRI, oncology
Abstract: There is a rapid expansion in the number of new anti-cancer drugs with remarkably different mechanisms of action that can augment traditional chemotherapy. As these agents are often used in combination with traditional chemotherapy testing the effects of these novel agents has proven difficult requiring large sample sizes to detect relatively small differences in patient survival. Despite the wide variety of mechanisms, most new drugs are thought to ultimately induce apoptosis of tumor cells or their supportive vasculature. Imaging agents that can non-invasively monitor apoptosis in response to these new drugs could therefore help streamline the drug development process. They may also help guide oncologists to identify those patients that could best benefit from a given therapeutic regimen, dose, or duration of drug. In this article we will outline the existing imaging agents and modalities that are currently undergoing clinical testing and those that could be rapidly translated into humans.
Export Options
About this article
Cite this article as:
Blankenberg G. Francis, Apoptosis Imaging: Anti-Cancer Agents in Medicinal Chemistry, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/187152009789377727
DOI https://dx.doi.org/10.2174/187152009789377727 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters Styrene Maleic Acid Neocarzinostatin Treatment for Hepatocellular Carcinoma
Current Medicinal Chemistry - Anti-Cancer Agents Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors
Current Gene Therapy The Effect of Lead Exposure on Selected Blood Inflammatory Biomarkers in Guinea pigs
Cardiovascular & Hematological Disorders-Drug Targets Association of p53 with Bid Induces Cell Death in Response to Etoposide Treatment in Hepatocellular Carcinoma
Current Cancer Drug Targets Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Pancreatic Neuroendocrine Tumors: Signal Pathways and Targeted Therapies
Current Molecular Medicine A Review on Anti-Cancer Activity of Some of the Oil-Soluble Organosulphur Compounds Against Colon Cancer
Current Traditional Medicine Alpha Fetoprotein is More than a Hepatocellular Cancer Biomarker: From Spontaneous Immune Response in Cancer Patients to the Development of an AFP-Based Cancer Vaccine
Current Molecular Medicine Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: Mitochondria as a Pharmacological Target: A Clue for Efficacy and a Reason for Toxicity (Executive Guest Editor: Nadezda Apostolova)]
Current Pharmaceutical Design Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins
Current Gene Therapy Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis
Current Medicinal Chemistry B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Current Molecular Medicine Multiple Functions of Rad9 for Preserving Genomic Integrity
Current Genomics A QSAR Study on Novel Series of Carbonic Anhydrase Inhibitors hCA IX—Tumor-Associated (Hypoxia)
Medicinal Chemistry The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Current Pharmaceutical Design Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer
Current Drug Discovery Technologies